New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.

CONCLUSIONS: The CELx HSF test is a well-characterized functional biomarker assay capable of identifying dynamic HER2-driven signaling dysfunction in tumor cells from HER2-negative breast cancer patients. This test has demonstrated efficacy of various HER2 targeted therapies in live tumor cells from the HSFs+ population and correlated the test result to HER2 drug response in mouse xenograft studies. The proportion of HER2-negative breast cancer patients found to have abnormal HER2 signaling in a 114 patient sample study, 20-25%, is significant. A clinical trial to evaluate the efficacy of anti-HER2 therapies in this patient population is warranted. PMID: 32036454 [PubMed - indexed for MEDLINE]

https://www.ncbi.nlm.nih.gov/pubmed/32036454?dopt=Abstract

Source: Clinical Breast Cancer - February 29, 2020 Category: Cancer & Oncology Authors: MacNeil IA, Burns DJ, Rich BE, Soltani SM, Kharbush S, Osterhaus NG, Sullivan BF, Hawkins DM, Pietruska JR, Laing LG Tags: J Cancer Res Clin Oncol Source Type: research